Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
44
MRVI Quote, Financials, Valuation and Earnings
Last price:
$3.43
Seasonality move
:
-3.88%
Day range:
$3.40 - $3.56
52-week range:
$1.67 - $6.21
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.56x
P/B ratio:
2.03x
Volume:
1.2M
Avg. volume:
1.4M
1-year change:
-36.83%
Market cap:
$497.4M
Revenue:
$259.2M
EPS (TTM):
-$0.84
Analysts' Opinion
-
Consensus RatingMaravai Lifesciences Holdings, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.93, Maravai Lifesciences Holdings, Inc. has an estimated upside of 14.54% from its current price of $3.43.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 41.69% downside risk from its current price of $3.43.
Fair Value
-
According to the consensus of 11 analysts, Maravai Lifesciences Holdings, Inc. has 14.54% upside to fair value with a price target of $3.93 per share.
MRVI vs. S&P 500
-
Over the past 5 trading days, Maravai Lifesciences Holdings, Inc. has underperformed the S&P 500 by -4.82% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Maravai Lifesciences Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Maravai Lifesciences Holdings, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Maravai Lifesciences Holdings, Inc. reported revenues of $41.6M.
Earnings Growth
-
Maravai Lifesciences Holdings, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Maravai Lifesciences Holdings, Inc. reported earnings per share of -$0.18.
Enterprise value:
808.2M
EV / Invested capital:
--
Price / LTM sales:
2.56x
EV / EBIT:
1.17x
EV / Revenue:
4.20x
PEG ratio (5yr expected):
-0.06x
EV / Free cash flow:
-11.87x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
1.05x
Gross Profit (TTM):
$37.7M
Return On Assets:
-21.46%
Net Income Margin (TTM):
-111.42%
Return On Equity:
-40.88%
Return On Invested Capital:
-23.17%
Operating Margin:
-21.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $419.5M | $276.8M | $192.3M | $69M | $41.6M | |
| Gross Profit | $250.5M | $119.1M | $37.7M | $31.5M | $5.1M | |
| Operating Income | $105.9M | -$39M | -$97.7M | -$9.9M | -$8.8M | |
| EBITDA | $149.9M | $16.3M | -$37.4M | $4.2M | $6.6M | |
| Diluted EPS | $0.18 | -$1.65 | -$0.84 | -$0.69 | -$0.18 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $687.5M | $835.5M | $700.9M | $679.1M | $325.9M | |
| Total Assets | $1.9B | $2.2B | $2.3B | $1.3B | $849.2M | |
| Current Liabilities | $114.4M | $115.7M | $78.3M | $63.2M | $61.6M | |
| Total Liabilities | $1.4B | $1.4B | $1.4B | $665.1M | $417.3M | |
| Total Equity | $453.6M | $841.7M | $892.3M | $613.1M | $431.9M | |
| Total Debt | $588.1M | $528.3M | $607.6M | $553.8M | $359.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $217.8M | $29.9M | -$50.7M | $13.1M | -$15.2M | |
| Cash From Investing | -$127.9M | -$32.3M | -$34.2M | -$9M | -$2.9M | |
| Cash From Financing | -$127.7M | $947K | -$249.6M | $809K | -$8.2M | |
| Free Cash Flow | $162.8M | -$11.7M | -$68.1M | $3.5M | -$18.1M | |
MRVI
Sector
Market Cap
$497.4M
$27.9M
Price % of 52-Week High
55.23%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
9.34%
-1.49%
1-Year Price Total Return
-36.83%
-16.66%
Beta (5-Year)
0.326
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.59
200-day SMA
Buy
Level
$2.64
Bollinger Bands (100)
Buy
Level
2.53 - 3.49
Chaikin Money Flow
Sell
Level
-10M
20-day SMA
Sell
Level
$3.61
Relative Strength Index (RSI14)
Sell
Level
46.81
ADX Line
Sell
Level
13.79
Williams %R
Buy
Level
-91.2281
50-day SMA
Buy
Level
$3.40
MACD (12, 26)
Buy
Level
0.08
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
3.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7663)
Sell
CA Score
(Annual)
Level (-1.5426)
Buy
Beneish M-Score
(Annual)
Level (-3.4139)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.8229)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, MRVI has received 5 Buy ratings 6 Hold ratings, and 0 Sell ratings. The MRVI average analyst price target in the past 3 months is $3.93.
-
Where Will Maravai Lifesciences Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Maravai Lifesciences Holdings, Inc. share price will rise to $3.93 per share over the next 12 months.
-
What Do Analysts Say About Maravai Lifesciences Holdings, Inc.?
Analysts are divided on their view about Maravai Lifesciences Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Maravai Lifesciences Holdings, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Maravai Lifesciences Holdings, Inc.'s Price Target?
The price target for Maravai Lifesciences Holdings, Inc. over the next 1-year time period is forecast to be $3.93 according to 11 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is MRVI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Maravai Lifesciences Holdings, Inc. is a Hold. 6 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MRVI?
You can purchase shares of Maravai Lifesciences Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Maravai Lifesciences Holdings, Inc. shares.
-
What Is The Maravai Lifesciences Holdings, Inc. Share Price Today?
Maravai Lifesciences Holdings, Inc. was last trading at $3.43 per share. This represents the most recent stock quote for Maravai Lifesciences Holdings, Inc.. Yesterday, Maravai Lifesciences Holdings, Inc. closed at $3.43 per share.
-
How To Buy Maravai Lifesciences Holdings, Inc. Stock Online?
In order to purchase Maravai Lifesciences Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MRVI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MRVI
Sector
P/E ratio
--
23.85x
PEG ratio
-0.06x
-0.01x
P/B ratio
2.03x
1.81x
Price / LTM sales
2.56x
1.58x
Growth Metrics
MRVI
Sector
Revenue growth
-39.69%
4.62%
Earnings growth
74.25%
10.5%
Revenue (5-year growth)
12.61%
6.5%
Earnings forecast
-$0.05
-$0.21
Profitability
MRVI
Sector
Profitability FY 2024
$105.7M
$3.6M
Return on invested capital
-23.17%
-31.87%
Return on assets
-21.46%
-28.18%
Return on equity
-40.88%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
5
Balance Sheet
MRVI
Sector
Total cash
$243.6M
$26.4M
Short term investments
--
$25.7M
Total assets
$1B
$76.9M
Long term debt
$359.8M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
